Results from the LEADER cardiovascular outcomes trial.

28 August 2017 (12:55 - 13:05)

Organised by:

About the speaker

Doctor Mansoor Husain

University of Toronto, Toronto (Canada)

3 More presentations in this session

Presentation thumbnail

Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Professor L. Ryden (Stockholm, SE)

Presentation thumbnail

Translating trials into practice – Clinical implications .

Professor M. Pfeffer (Boston, US)

Presentation thumbnail

Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Professor L. Ryden (Stockholm, SE) Professor M. Pfeffer (Boston, US) Doctor M. Husain (Toronto, CA)

Access the full session

Session thumbnail

GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?

The Event

ESC Congress 2017

28 August 2017 12:55 CET

You may be interested in

Congress Presentation

The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease

1 September 2024

Webinar

How should I manage LEAD

5 February 2020

Congress Presentation

Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials

2 September 2019

ESC TV Today

Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty

6 November 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources